[ET Net News Agency, 23 September 2021] Luye Pharma Group Ltd. (02186) said the group's
new drug Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD or LY30410) has
received Marketing Authorization (MA) from the Medicines & Healthcare products Regulatory
Agency in the United Kingdom.
Rivastigmine MD is an innovative delivery system drug developed by the group for the
treatment of mild to moderate dementia associated with Alzheimer's disease. (RC)